Form 4: Aquestive CMO's RSU Vesting Leads to Tax Withholding

Aquestive Therapeutics' Chief Medical Officer, Carl N. Kraus, had 10,819 shares withheld for tax obligations related to RSU vesting.

Summary

• Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, Inc. (AQST), reported a transaction on August 9, 2025.
• The transaction involved the disposition of 10,819 shares of common stock.
• These shares were withheld by the company to cover tax withholding obligations arising from the vesting of previously granted Restricted Stock Units (RSUs).
• The shares were valued at $3.9 per share for this purpose.
• Following this transaction, Carl N. Kraus beneficially owns 302,747 shares of Aquestive Therapeutics common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine transaction where shares were withheld for tax purposes upon RSU vesting, which is a common and expected event for executives receiving equity compensation. It does not indicate a discretionary sale or any negative operational news, thus maintaining a neutral to slightly positive sentiment due to the underlying RSU vesting.

Positives

• The transaction is a routine administrative event related to the vesting of equity compensation, indicating continued alignment of management interests with shareholders.
• It does not represent a discretionary sale by the insider, which could otherwise be interpreted negatively.

Negatives

• The disposition of 10,819 shares, even for tax purposes, reduces the direct share count held by the insider, though this is a standard practice for RSU vesting.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Industry Context

This filing reports a routine insider transaction related to equity compensation, which is a common practice across all industries for publicly traded companies. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of Restricted Stock Units (RSUs) is a standard and widely adopted mechanism for equity compensation across publicly traded companies globally.
• This transaction aligns with common corporate governance and compensation practices observed in comparable pharmaceutical and biotechnology companies that utilize equity incentives for executive retention and alignment.

Related Party Transactions

• The disposition of 10,819 shares of common stock by Carl N. Kraus, Chief Medical Officer, to Aquestive Therapeutics, Inc. for tax withholding purposes related to RSU vesting constitutes a disclosed related party dealing, which is a standard component of executive equity compensation plans.

Stakeholder Impact

• Shareholders: The transaction is a routine part of the company's equity compensation plan, which aims to align management incentives with shareholder interests. The shares withheld for tax purposes reduce the number of shares that would otherwise enter the market from this specific vesting event.
• Employees: This filing highlights the company's use of Restricted Stock Units as a form of executive compensation, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the withholding of shares for tax obligations upon the vesting of Restricted Stock Units (RSUs). This is a standard practice for equity compensation and does not signal any fundamental change in the company's operations, financial health, or future outlook. As such, it provides no new information that would warrant a change in investment recommendation, leading to a 'hold' stance.

Keywords

Aquestive Therapeutics, AQST, Carl N Kraus, Chief Medical Officer, CMO, SEC Form 4, Insider Transaction, RSU, Restricted Stock Units, Tax Withholding, Equity Compensation, Beneficial Ownership